Stock market today: S&P 500 rallies on cooling fears of US-China trade war
Investing.com -- CERo Therapeutics (NASDAQ:CERO), a T cell therapy biotech company, is open to licensing deals or a potential sale while awaiting data on its lead asset, according to Axios, citing CEO Chris Ehrlich.
The company is developing next-generation engineered T cell therapeutics for cancer treatment through its proprietary approach that combines characteristics of both innate and adaptive immunity into a single therapeutic construct.
CERo’s novel cellular immunotherapy platform redirects patient-derived T cells to eliminate tumors by incorporating engulfment pathways that use phagocytic mechanisms to destroy cancer cells. The company refers to these as Chimeric Engulfment Receptor T cells, or "CER-T."
The company believes its CER-T cells may allow broader therapeutic application than currently approved chimeric antigen receptor (CAR-T) cell therapy, potentially spanning both hematological malignancies and solid tumors.
CERo has already begun clinical trials for its lead product candidate CER-1236 for hematological malignancies.
Cell therapy companies have recently attracted significant interest from major pharmaceutical companies, positioning CERo as a potential acquisition target in the sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.